SEC Form 3

FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			or Sec	tion 30(h)	of the Investment Company Act of	1940				
1. Name and Address of Reporting Person <sup>®</sup> Baker Brothers Life Sciences			2. Date of Eve Requiring Sta (Month/Day/Y	tement	3. Issuer Name and Ticker or Trading Symbol IDERA PHARMACEUTICALS, INC. [ IDP ]					
(Last) (First) (Middle) 667 MADISON AVENUE		03/24/2006		4. Relationship of Reporting Person(s) to Is (Check all applicable) Director X 10% Ov Officer (give title Other (s below) below)		er cify	<ul> <li>5. If Amendment, Date of Original Filed (Month/Day/Year) 03/29/2006</li> <li>6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting</li> </ul>			
(Street) NEW YORK N		10021	_					Person	by More than One	
(City) (S	tate)	(Zip)		on Doriy	vative Securities Beneficial					
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership 4. Nat		Nature of Indirect Beneficial Ownership str. 5)		
Common Stock <sup>(1)</sup>					4,595,732 <sup>(3)</sup>	Ι	S	ee Footnote <sup>(2)</sup>	Footnote <sup>(2)</sup>	
					ive Securities Beneficially rants, options, convertible		5)			
1. Title of Derivative Security (Instr. 4) 2. Date Exercise Expiration Date (Month/Day/Year Date Exercise			cisable an ate		ties	(Instr. 4) 4. (or		6. Nature of Indirect Beneficial Ownership (Instr. 5)		
				Expiratio Date	n Title	Amount or Number of Shares	Exercis Price of Derivati Security	f or Indirect ive (I) (Instr. 5)		
Warrant			09/26/2006	09/26/201	1 Common Stock	3,446,799	0.65	5 I	See Footnote <sup>(3)</sup>	
1. Name and Addre Baker Brothe LLC			ipital (GP),							
(Last) 667 MADISON A	(First) AVENUE	(Mi	iddle)							
(Street) NEW YORK	NY	10	0021	_						
(City)	(State)	(Zij	p)							
1. Name and Addre BAKER JUL		ing Person <sup>*</sup>								
(Last) (First) (Middle 667 MADISON AVENUE			iddle)							
(Street) NEW YORK	NY	10	0021							
(City)	(State)	(Zij	p)							

1. Name and Address of Reporting Person <sup>*</sup> BAKER FELIX								
(Last) (First) (Middle) 667 MADISON AVENUE								
(Street) NEW YORK	NY	10021						
(City)	(State)	(Zip)						

## Explanation of Responses:

1. In addition to Baker Brothers Life Sciences Capital (GP), LLC, this Form 3 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as Baker Brothers Life Sciences Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (Continued in footnote 2.)

2. However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.

3. Represents securities owned directly by Baker Brothers Life Sciences, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC. Felix J. Baker and Julian C. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.

/s/ Julian C. Baker, as	
Managing Member of Baker	08/17/2006
Brothers Life Sciences Capital	00/1//2000
<u>(GP), LLC</u>	
<u>/s/ Julian C. Baker</u>	08/17/2006
<u>/s/ Felix J. Baker</u>	08/17/2006
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.